| Literature DB >> 35874554 |
Tao Chen1, Huiying Zhu2, Qingyuan Su1.
Abstract
Methods: A retrospective study was conducted on all patients with CHD who were admitted to CR and completed cardiopulmonary exercise tests (CPET) in Guangdong Hospital of traditional Chinese medicine. According to the risk stratification method of CHD, all participants were divided into three groups: low, moderate, and high risk. The training target heart rates (HRt) of each participant were calculated according to the formula of heart-rate-reserve (HRR), maximum-heart-rate (MHR), target-heart-rate (THR), and anaerobic threshold (AT) method provided in the guideline. Among them, the HRR method using the maximum-heart-rate obtained by the age formula was named "HRR method A," and that using the actual measured peak heart rate was named "HRR method B." For the three groups, the effectiveness and safety indexes at the target-heart-rate zone set by the different formulas above are counted and compared using CPET data.Entities:
Year: 2022 PMID: 35874554 PMCID: PMC9307357 DOI: 10.1155/2022/1647809
Source DB: PubMed Journal: Cardiol Res Pract ISSN: 2090-0597 Impact factor: 1.990
Risk stratification of cardiovascular events during exercise.
| Item | Risk stratification | |||
|---|---|---|---|---|
| Low-risk | Moderate-risk | High-risk | ||
| Exercise test index | Angina | No | Maybe yes | Yes |
| Asymptomatic, with myocardial ischemia and ECG changes | No | Maybe yes, ST segment down shift <2 mm | Yes, ST segment down shift ≥2 mm | |
| Other obvious discomfort symptoms (e.g., dyspnea, dizziness) | No | Maybe yes | Yes | |
| Complex ventricular arrhythmias | No | No | Yes | |
| Hemodynamic response | Normal | Normal | Abnormal | |
| Functional reserve | ≥7METs | 5.0–7.0 METs | ≤5 METs | |
|
| ||||
| Nonexercise test index | LVEF | ≥50% | 40%–50% | <40% |
| History of sudden death/sudden death | No | No | Yes | |
| Resting complex ventricular arrhythmias | No | No | Yes | |
| Complications of MI or revascularization | No | No | Yes | |
| Myocardial ischemia after MI or revascularization | No | No | Yes | |
| Congestive heart failure | No | No | Yes | |
| Clinical depression | No | No | Yes | |
All low-risk items match belong to low-risk groups; any high-risk item matches belong to high-risk group. ECG, electrocardiography. LVEF, left ventricular ejection fraction. MI, myocardial infarction.
Basic clinical data of patients.
| All Patients ( | Low-risk ( | Moderate-risk ( | High-risk ( |
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of patients (%) | Mean (SD) | No. of patients (%) | Mean (SD) | No. of patients (%) | Mean (SD) | No. of patients (%) | Mean (SD) | |||||
| Age, y | 324 | 62.8 (9.9) | 15 | 57.3 (6.7) | 77 | 60.0 (10.3) | 232 | 64.1 (9.7) | 0.00 | 0.63 | 0.04 | 0.01 |
| Men | 210 (64.8) | 14 (93.3) | 62 (80.5) | 134 (57.8) | 0.00 | 0.41 | 0.01 | 0.00 | ||||
| BMI, | ||||||||||||
| kg/m2 | 324 | 24.2 (3.4) | 15 | 22.9 (2.0) | 77 | 23.8 (2.6) | 232 | 24.4 (3.6) | 0.14 | 0.39 | 0.05 | 0.31 |
| LVEF, % | 324 | 65.9 (8.5) | 15 | 66.9 (6.7) | 77 | 65.9 (7.1) | 232 | 65.8 (9.0) | 0.89 | 0.91 | 0.89 | 1.00 |
| Functional reserve, METs | 324 | 5.1 (1.5) | 15 | 8.1 (0.7) | 77 | 6.1 (0.7) | 232 | 4.6 (1.3) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| ||||||||||||
| Medications | 185 (57.1) | 9 (60) | 37 (48.1) | 139 (59.9) | 0.21 | 0.39 | 1.00 | 0.07 | ||||
P #, P value of comparison among three groups; Pa, P value of comparison between low-risk and moderate-risk group; Pb, P value of comparison between low-risk and high-risk group; Pc, P value of comparison between moderate-risk and high-risk group. BMI, body mass index; LVEF, left ventricular ejection fraction.
Medical history data of patients.
| All Patients ( | Low-risk ( | Moderate-risk ( | High-risk ( |
|
|
|
| |
|---|---|---|---|---|---|---|---|---|
| No. of patients (%) | No. of patients (%) | No. of patients (%) | No. of patients (%) | |||||
| Type of CHD | ||||||||
| MI | 91 (28.1) | 5 (33.3) | 18 (23.4) | 68 (29.3) | 0.76 | 0.63 | 0.80 | 0.70 |
| HF | 26 (8.0) | 0 | 0 | 26 (11.2) | 0.00 | — | 0.38 | 0.00 |
| post-PCI | 213 (65.7) | 12(80) | 48 (62.3) | 153 (65.9) | 0.42 | 0.19 | 0.40 | 0.57 |
| post-CABG | 4 (1.2) | 0 | 0 | 4 (1.7) | 0.45 | — | 1.00 | 0.56 |
| Incomplete revascularization | 56 (17.3) | 0 | 0 | 56 (24.1) | 0.00 | — | 0.03 | 0.00 |
| Complex VA | 23 (7.1) | 0 | 0 | 23 (9.9) | 0.01 | — | 0.37 | 0.00 |
| History of other diseases | ||||||||
| Hypertension | 207 (63.9) | 7 (46.7) | 44 (57.1) | 156 (67.2) | 0.10 | 0.46 | 0.10 | 0.11 |
| Diabetes | 128 (39.5) | 4 (26.7) | 32 (41.6) | 92 (39.7) | 0.56 | 0.28 | 0.32 | 0.77 |
| Dyslipidemia | 107 (33) | 3 (20) | 25 (32.5) | 79 (34.1) | 0.53 | 0.51 | 0.40 | 0.80 |
| Carotid atherosclerosis | 153 (47.2) | 6 (40) | 40 (51.9) | 107 (46.1) | 0.57 | 0.40 | 0.65 | 0.38 |
P #, P value of comparison among three groups; Pa, P value of comparison between low-risk and moderate-risk group; Pb, P value of comparison between low-risk and high-risk group; Pc, P value of comparison between moderate-risk and high-risk group. CHD, coronary heart disease; MI, myocardial infarction; HF, heart failure; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; VA, complex ventricular arrhythmia.
The main outcome indicators of CPET.
| All Patients ( | Low-risk ( | Moderate-risk ( | High-risk ( |
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of patients (%) | Mean (SD) | No. of patients (%) | Mean (SD) | No. of patients (%) | Mean (SD) | No. of patients (%) | Mean (SD) | |||||
| HRAT, bpm | 311 | 98 (13.0) | 15 | 103 (12.7) | 77 | 99 (11.8) | 219 | 97 (13.3) | 0.19 | 0.59 | 0.28 | 0.58 |
| ATMETs, METs | 311 | 3.2 (0.7) | 15 | 4.3 (0.7) | 77 | 3.6 (0.6) | 219 | 3.0 (0.7) | 0.00 | 0.00 | 0.00 | 0.00 |
| VO2AT, ml/kg/min | 311 | 11.3 (2.5) | 15 | 15.2 (2.3) | 77 | 12.6 (2.0) | 219 | 10.6 (2.3) | 0.00 | 0.00 | 0.00 | 0.00 |
| VO2AT/pred%, % | 311 | 43.1 (13.6) | 15 | 50.9 (13.3) | 77 | 46.6 (10.2) | 219 | 41.4 (14.3) | 0.00 | 0.53 | 0.03 | 0.01 |
| VO2peak, ml/kg/min | 324 | 17.8 (5.3) | 15 | 28.3 (2.6) | 77 | 21.2 (2.8) | 232 | 16.0 (4.7) | 0.00 | 0.00 | 0.00 | 0.00 |
| VO2peak/pred%, % | 324 | 69.9 (17.4) | 15 | 94.3 (18.8) | 77 | 78.4 (13.3) | 232 | 65.6 (16.2) | 0.00 | 0.00 | 0.00 | 0.00 |
| HRpeak, bpm | 324 | 125 (20.9) | 15 | 147 (14.8) | 77 | 132 (15.9) | 232 | 121 (21.1) | 0.00 | 0.01 | 0.00 | 0.00 |
| HRmax, bpm | 324 | 157 (10.4) | 15 | 163 (6.7) | 77 | 160 (10.3) | 232 | 156 (10.4) | 0.00 | 0.65 | 0.06 | 0.02 |
| RHR, bpm | 324 | 73 (10.5) | 15 | 71 (13.0) | 77 | 73 (9.7) | 232 | 73 (10.6) | 0.62 | 0.59 | 0.28 | 0.58 |
| Complex VA in test | 27 (8.3) | 0 | 0 | 27 (11.6) | 0.00 | - | 0.38 | 0.00 | ||||
| ECG positive reaction | 28 (8.6) | 0 | 0 | 28 (12.1) | 0.00 | - | 0.23 | 0.00 | ||||
| ECG suspicious positive reaction | 42 (13.0) | 0 | 13 (16.9) | 29 (12.5) | 0.19 | 0.12 | 0.23 | 0.33 | ||||
| With Normal VO2AT | 228 (70.4) | 12 (80) | 59 (76.6) | 157 (67.7) | 0.23 | 1.00 | 0.48 | 0.14 | ||||
| With Normal VO2peak | 69 (21.3) | 12 (80) | 26 (33.8) | 31 (13.4) | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| With Roughly normal VO2peak | 27 (8.3) | 1 (6.7) | 7 (9.1) | 19 (8.2) | 0.94 | 1.00 | 1.00 | 0.81 | ||||
P #, P value of comparison among three groups; Pa, P value of comparison between low-risk and moderate-risk group; Pb, P value of comparison between low-risk and high-risk group; Pc, P value of comparison between moderate-risk and high-risk group. HRAT, heart rate at anaerobic threshold; ATMETS, metabolic equivalent at anaerobic threshold; VO2AT, oxygen uptake at anaerobic threshold; Pred, predicted value; VO2peak, oxygen uptake at peak; HR peak, heart rate at peak; HRmax, age-predicted maximum-heart-rate; RHR, resting heart rate; VA, ventricular arrhythmia; ECG, electrocardiography.
The comparison of effectiveness indicators.
| Intensity technique | All patients ( | Low-risk ( | Moderate-risk ( | High-risk ( |
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of patients (%) | Mean (SD) |
| No. of patients (%) | Mean (SD) | No. of patients (%) | Mean (SD) | No. of patients (%) | Mean (SD) | |||||
| Mean value of target-heart-rate set by exercise intensity techniques, (bpm) | |||||||||||||
| HRR-m A | 324 | 98 (8.5) | 0.45 | 15 | 99 (9.7) | 77 | 99 (7.2) | 232 | 98 (8.8) | 0.77 | 1.00 | 0.96 | 0.79 |
| HRR-m B | 324 | 88 (11.0) | 0.00 | 15 | 94 (10.5) | 77 | 91 (9.5) | 232 | 87 (11.3) | 0.01 | 0.54 | 0.08 | 0.09 |
| MHR-m | 324 | 79 (5.2) | 0.00 | 15 | 81 (3.4) | 77 | 80 (5.1) | 232 | 78 (5.2) | 0.00 | 0.65 | 0.06 | 0.02 |
| THR-m | 324 | 93 (10.5) | 0.00 | 15 | 91 (13.0) | 77 | 93 (9.7) | 232 | 93 (10.6) | 0.62 | 0.90 | 0.73 | 0.81 |
| AT-m | 311 | 98 (13.0) | 15 | 103 (12.7) | 77 | 99 (11.8) | 219 | 97 (13.3) | 0.19 | 0.59 | 0.28 | 0.58 | |
|
| |||||||||||||
| Frequencies of whose target HR lower than HRAT. | |||||||||||||
| HRR-m A | 164 (50.6) | 9 (60.0) | 37 (48.1) | 118 (50.9) | 0.69 | 0.40 | 0.49 | 0.67 | |||||
| HRR-m B | 268 (82.7) | 11 (73.3) | 66 (85.7) | 191 (82.3) | 0.49 | 0.42 | 0.60 | 0.49 | |||||
| MHR-m | 307 (94.8) | 14 (93.3) | 72 (93.5) | 221 (94.8) | 0.81 | 1.00 | 1.00 | 0.76 | |||||
| THR-m | 208 (64.2) | 12 (80.0) | 56 (72.7) | 140 (60.3) | 0.06 | 0.79 | 0.13 | 0.051 | |||||
|
| |||||||||||||
| Frequencies of whose target HR higher than HRAT. | |||||||||||||
| HRR-m A | 160 (49.4) | 6 (40.0) | 40 (51.9) | 114 (49.1) | 0.69 | 0.40 | 0.49 | 0.67 | |||||
| HRR-m B | 53 (16.4) | 4 (26.7) | 11 (14.3) | 38 (16.4) | 0.50 | 0.42 | 0.50 | 0.66 | |||||
| MHR-m | 16 (4.9) | 1 (6.7) | 5 (6.5) | 10 (4.3) | 0.71 | 1.00 | 0.51 | 0.64 | |||||
| THR-m | 106 (32.7) | 3 (20.0) | 20 (26.0) | 83 (35.8) | 0.16 | 0.87 | 0.21 | 0.11 | |||||
P, , P value of comparison between each intensity technique and AT-m by paired t-test; P#, P value of comparison among three groups; Pa, P value of comparison between low-risk and moderate-risk group; Pb, P value of comparison between low-risk and high-risk group; Pc, P value of comparison between moderate-risk and high-risk group. HRR-m A, heart-rate-reserve method A; HRR-m B, heart-rate-reserve method B; MHR-m, max-heart-rate method; THR-m: target-heart-rate method; AT-m: anaerobic threshold method.
Comparison of safety indicators in intensity techniques.
|
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|
| No. of patients | (%) of all high-risk patients ( | (%) in all ECG positive reaction patients | No. of patients | (%) of all high-risk patients ( | (%) in all Complex VA patients ( | No. of patients | No. of patients | |
| HRR-m A | 7 | 3.0 | 25 | 18 | 7.8 | 66.7 | 1 | 2 |
| HRR-m B | 1 | 0.4 | 3.6 | 9 | 3.9 | 33.3 | 0 | 1 |
| MHR-m | 0 | 0 | 0 | 5 | 2.2 | 18.5 | 1 | 1 |
| THR-m | 4 | 1.7 | 14.3 | 13 | 5.6 | 48.1 | 1 | 1 |
| AT-m | 2 | 0.9 | 7.1 | 14 | 6.0 | 51.9 | 1 | 2 |
| P△ | 0.00 | 0.00 | 0.00 | 0.00 | ||||
P △, P value of the consistency comparison among the five methods in the distribution of the safety indicators (using the nonparametric test of Related Samples—Cochran's Q test, ) in the high-risk group or all the people with this safety indicators. c, no. of patients with nonsustained ventricular tachycardia; f, no. of patients with bundle branch block; HRR-m A, heart-rate-reserve method A; HRR-m B, heart-rate-reserve method B; MHR-m, max-heart-rate method; THR-m, target-heart-rate method; AT-m, anaerobic threshold method. Among the above-mentioned patients with ECG abnormalities, most of them with positive reaction have a medical history of hypertension, normal LVEF, normal anaerobic threshold, decreased functional reserve, and most of them use β-blocker medications, but there was no significant difference compared with negative patients (P > 0.05).